RETA Stock News

Reata (RETA) gets FDA acceptance for the filing of new drug application supplement approval for Skyclarys' release.

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock?

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global biopharmaceutical company focused on developing a

Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.

Reata Pharmaceuticals, Inc. (NASDAQ:RETA ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Warren Huff - Chairman and Chief Executive Officer Dawn Bir - Executive Vice Pr

Reata Pharmaceuticals is scrapping development of a kidney disease drug and put up mixed earnings Wednesday. RETA stock tumbled.

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global, biopharmaceutical, company focused on developing

Reata graduated to owning a commercial pharmaceutical product on February 28. Projecting timing for Skyclarys or any new therapy's revenue ramp is difficult.

Investors may want to keep an eye on biotech growth stocks, which are typically associated with the risk-on trade. Case in point: The sector ran up in January, but when the broader-market rally fizzle

Reata Pharmaceuticals stock is soaring on the back of a recent FDA approval for a new rare disease drug. Calliditas Therapeutics stock recently jumped higher in response to positive trial results for

Reata Pharmaceuticals (RETA) stock more than doubles this year, owing to approval for its rare disease drug.

After a marketwide downturn in 2022, most healthcare stocks are still trading at multiyear lows right now. GE Healthcare Technologies and Reata Pharmaceuticals have shrugged off this negative sentimen

Texas-based biotechnology company Reata Pharmaceuticals, Inc. (NASDAQ:RETA) lulled shareholders to sleep in 2022. The news flow was light, the trading pattern sideways and volume virtually nonexistent

David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 20

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical company focused on developing and comm